Treatment of Relapsed or Refractory B-cell Malignancies by CD19 Chimeric Antigen Receptor (CAR)-Modified T Cells

Study Summary

This is a single arm, open-label, phase 1/2 study to evaluate the safety and efficacy of anti-CD19 CAR-T cells in patients with relapsed or refractory B cell Malignancies.

Interventions

Study Locations

Facility	City	State	Country
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei	China

Official Trial Information

View on ClinicalTrials.gov